Pegylated interferon α2b versus pegylated interferon α2a for chronic hepatitis C: The unreached goal of superiority

References 

1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965
   • Abstract
   • Full Text
   • Full-Text PDF (110 KB)
   • CrossRef
2. Fried MW, Shiffman M, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirn for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982
   • CrossRef
3. Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hep. 2007;14:721729
4. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580–593
   • CrossRef
5. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34:395–403
   • MEDLINE
   • CrossRef
6. Reddy KR, Shiffman ML, Morgan TR, Zeuzem S, Hadziyannis S, Hamzeh FM, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol. 2007;5:124–129
   • Abstract
   • Full Text
   • Full-Text PDF (131 KB)
   • CrossRef
7. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology. 2007;46:1688–1694
   • CrossRef
8. Kanwal F, Hoang T, Spiegel BM, et al. Predictors of treatment in patients with chronic hepatitis C infection: role of patients versus nonpatient factors. Hepatology. 2007;46:1741–1749
   • CrossRef
9. Backus LI, Boothroyd DB, Phillips BR, Mole LA, Elsen S, Dominitz JA, et al. Predictors of response of US veterans to treatment for hepatitis C virus. Hepatology. 2007;46:37–47
   • MEDLINE
   • CrossRef
10. Witthoeft T, Hueppe D, John C, Golz J, Meyer U, Heyne R, et al. Efficacy and safety of peginterferon alfa-2a or -2b plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Germany: the PRACTICE Study. J Hepatol. 2008;48:S315
    • Full-Text PDF (62 KB)
    • CrossRef
11. Ascione A, De Luca M, Tartaglione MT, Lampasi F, Galeota Lanza A, Picciotto FP, et al. Peginterferon alpha-2a plus ribavirin versus peginterferon alpha-2b plus ribavirin in naive patients with chronic hepatitis C virus infection: results of a prospective randomised trial. J Hepatol. 2008;48:S370
    • Full-Text PDF (55 KB)
    • CrossRef
12. Rumi MG, Aghemo A, Prati GM, D’Ambrosio R, Donato MF, Soffredini R, et al. Randomized study of PEG-interferon-α2a plus ribavirin versus PEG-interferon-α2b plus ribavirin in chronic hepatitis C. Gastroenterology, in press. doi:10.1053/j.gastro.2009.08.071.